Zhejiang Tailin Bioengineering Co Ltd (300813) - Total Assets
Based on the latest financial reports, Zhejiang Tailin Bioengineering Co Ltd (300813) holds total assets worth CN¥934.06 Million CNY (≈ $136.68 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Zhejiang Tailin Bioengineering Co Ltd's book value for net asset value and shareholders' equity analysis.
Zhejiang Tailin Bioengineering Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Zhejiang Tailin Bioengineering Co Ltd's total assets have evolved over time, based on quarterly financial data.
Zhejiang Tailin Bioengineering Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Tailin Bioengineering Co Ltd's total assets of CN¥934.06 Million consist of 65.9% current assets and 34.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 27.6% |
| Accounts Receivable | CN¥70.88 Million | 7.4% |
| Inventory | CN¥144.13 Million | 15.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥10.92 Million | 1.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Zhejiang Tailin Bioengineering Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Zhejiang Tailin Bioengineering Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Tailin Bioengineering Co Ltd's current assets represent 65.9% of total assets in 2024, an increase from 60.6% in 2013.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2024, up from 18.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 15.0% of total assets.
Zhejiang Tailin Bioengineering Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Tailin Bioengineering Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Zhejiang Tailin Bioengineering Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.88 | 4.50 | 4.48 |
| Quick Ratio | 2.78 | 3.38 | 3.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥404.50 Million | CN¥495.05 Million | CN¥331.03 Million |
Zhejiang Tailin Bioengineering Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Tailin Bioengineering Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.01 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | CN¥959.91 Million |
| Market Capitalization | $454.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Tailin Bioengineering Co Ltd's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Tailin Bioengineering Co Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Tailin Bioengineering Co Ltd (2013–2024)
The table below shows the annual total assets of Zhejiang Tailin Bioengineering Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥959.91 Million ≈ $140.46 Million |
-1.40% |
| 2023-12-31 | CN¥973.51 Million ≈ $142.45 Million |
+5.51% |
| 2022-12-31 | CN¥922.66 Million ≈ $135.01 Million |
+40.68% |
| 2021-12-31 | CN¥655.87 Million ≈ $95.97 Million |
+21.46% |
| 2020-12-31 | CN¥539.99 Million ≈ $79.02 Million |
+102.31% |
| 2019-12-31 | CN¥266.91 Million ≈ $39.06 Million |
+4.62% |
| 2018-12-31 | CN¥255.12 Million ≈ $37.33 Million |
+31.78% |
| 2017-12-31 | CN¥193.59 Million ≈ $28.33 Million |
+24.12% |
| 2016-12-31 | CN¥155.97 Million ≈ $22.82 Million |
+18.86% |
| 2015-12-31 | CN¥131.22 Million ≈ $19.20 Million |
+67.39% |
| 2014-12-31 | CN¥78.39 Million ≈ $11.47 Million |
-4.37% |
| 2013-12-31 | CN¥81.97 Million ≈ $12.00 Million |
-- |
About Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd offers life science system solutions in China. The company offers cell and gene therapy solutions, including biosafety ferret isolators, sterile pig preparation solutions, aseptic filling workstation, cell preparation workstation, and robotic packaging workstations; drug development and sterile production solutions, comprising sterile packaging, highly activ… Read more